GlaxoSmithKline Inc
(LtoR) Christophe Weber President of GlaxoSmithKline Vaccines, Gent university researcher Claus Bachert and Princess Mathilde of Belgium pose during an award ceremony of the GSK vaccines, an award given every three years to a French-speaking and a Flemish Belgians medical researchers, on June 19, 2013 in Brussels.
Connections
Quotes
It has been truly inspiring to see how 24 different organizations can come together to deliver so successfully on a joint project. Particularly significant contributions have been made by ChemAxon, Bristol-Myers Squibb, GlaxoSmithKline and Roche.
You are in good shape with Pfizer. It is cheap ... GlaxoSmithKline is my favorite in the group. That is even better.
Further expansion will only depend on the growth of the existing market. However, looking into our competency and our existing business relationship with GlaxoSmithKline, we are optimistic that for any future growth, the first opportunity will come to usMore quotes »
Newsday's coverage
-
UK alleges GSK paid off competitors to delay drugs
-- Britain's competition watchdog has accused GlaxoSmithKline of paying off competitors to delay launches of their own versions of GSK's best-selling antidepressant, Seroxat.The Office of Fair Trading alleges GlaxoSmithKline concluded agreements which infringed Read more »
Around the web
-
Vaccine Against HPV Has Cut Infections in Teenage Girls
girls. The first vaccine against HPV, Merck's Gardasil , was approved by the Food and Drug Administration in 2006. Cerverix, from GlaxoSmithKline, was approved in 2009. In the first four years of immunizations, infections from the four strains of human papillomavirus 3:32 PM from NPR Read more »
-
GlaxoSmithKline Negotiating $1 Billion Sale of Thrombosis Drugs to Aspen Pharmacare Ltd.
up-to-date has never been simpler. Sign up for the free GenePool newsletter today! GlaxoSmithKline is discussing the sale of its thrombosis drug brands Arixtra and Fraxiparine, along with a related French factory, to Aspen Pharmacare in a deal that could be 11:29 AM from Biospace Read more »
-
Apple’s iWatch Potential, GlaxoSmithKline Fields Drug Bid, and 3 More Hot Stocks
Apple (NASDAQ:AAPL): Jefferies’ analyst Peter Misek believes that the speculated iWatch will be more of a hobby line for Apple, but not a full-blown product line for the company. Misek keeps a broad price range of $50-$300 on the device — presumably availa from Wall Street Cheat Sheet Read more »
-
Glaxo Gets Offer for Thombosis Brands
transaction is aligned to GSK’s strategy of focusing on products with the most growth potential and the delivery of its pipeline. GlaxoSmithKline – one of the world’s leading research-based pharmaceutical and healthcare companies – is committed to improving from Drugs.com Read more »
-
South Africa's Aspen to acquire thrombosis drugs from GSK
- Aspen Pharmacare said on Tuesday it would acquire the Arixtra and Fraxiparine/Fraxodi brands of thrombosis drug from GlaxoSmithKline, except in China, Pakistan and India. The South African drugmaker also said it would buy the specialised sterile production from Reuters Read more »
